Publication
International arbitration report
In this edition, we focused on the Shanghai International Economic and Trade Arbitration Commission’s (SHIAC) new arbitration rules, which take effect January 1, 2024.
United States | Publication | January 2021
On November 30, 2020, California’s new emergency, temporary COVID-19 standards took effect. Title 8, California Code of Regulations, sections 3205 through 3205.4. See our recent alert and blog post for more information.
On December 14, 2020, California’s governor issued an Executive Order which modifies the emergency COVID-19 regulations by reducing the required quarantine or isolation period required by Section 3205(c)(10) (“Exclusion of COVID-19 cases”) and (c)(11) (“Return to work criteria”) from 14 days to 10 days. Thus, for example, employers need only exclude employees with COVID-19 exposure from the workplace for 10 days (as opposed to the original 14 days) after the last known COVID-19 exposure to a COVID-19 case.
On December 16, 2020, the National Retail Federation, the National Federation of Independent Business and three small employers filed a lawsuit in San Francisco Superior Court to block Cal/OSHA from enforcing the new COVID-19 regulations. The complaint describes the regulations as unnecessary, “scientifically unsupported” and “arbitrary and capricious.” We will continue to monitor activity in this case.
Publication
In this edition, we focused on the Shanghai International Economic and Trade Arbitration Commission’s (SHIAC) new arbitration rules, which take effect January 1, 2024.
Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023